---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-015082"
form_type: "8-K"
ticker: "CYDY"
cik: "0001175680"
company_name: "CytoDyn Inc."
filed_at: "2022-10-19T23:59:59+00:00"
generated_at: "2026-06-23T02:35:10.858062+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# CytoDyn director Scott Kelly resigns; Stephen Simes appointed to board.

## Summary
- Scott Kelly resigned as director effective Oct 13, 2022; remains CMO and Head of Business Development.
- Stephen Simes appointed director same day, filling Kelly's vacancy.
- Simes has 40+ years pharma experience, former CEO of BioSante and RestorGenex, director at several firms.
- Simes compensated per nonemployee director policies with cash retainers and stock options.
- No disclosable transactions or family relationships between Simes and other officers/directors.

## SEC filing metadata
- accession: 0001558370-22-015082
- form_type: 8-K
- ticker: CYDY
- cik: 0001175680
- company_name: CytoDyn Inc.
- filed_at: 2022-10-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175680/000155837022015082/0001558370-22-015082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175680/000155837022015082/cydy-20221013x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-015082
- JSON: https://secwatch.observer/filing/0001558370-22-015082.json
- Plain text: https://secwatch.observer/filing/0001558370-22-015082.txt

## Key facts
- Executive change
  Stephen M. Simes was appointed as Director at CytoDyn Inc..
  - Action: appointed
  - Role: Director
  source text: On October 13, 2022, the Company’s Board of Directors (the “Board”) approved the appointment of Stephen M. Simes (“Mr. Simes”) as a director of the Company, effective October 13, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837022015082/0001558370-22-015082-index.htm
- Executive change
  Scott A. Kelly resigned as Director at CytoDyn Inc..
  - Action: resigned
  - Role: Director
  source text: On October 13, 2022, Scott A. Kelly, M.D. (“Dr. Kelly”) provided written notice to the Board Chair of CytoDyn Inc. (the “Company”) of his resignation as a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175680/000155837022015082/0001558370-22-015082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.